These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 28264701

  • 1. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS.
    Breast Cancer Res; 2017 Mar 06; 19(1):23. PubMed ID: 28264701
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I.
    Clin Cancer Res; 2014 Jun 01; 20(11):2922-32. PubMed ID: 24687923
    [Abstract] [Full Text] [Related]

  • 3. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT, Holen I, Dear TN, Hunter K, Brown HK.
    Bone; 2014 Sep 01; 66(100):240-50. PubMed ID: 24971713
    [Abstract] [Full Text] [Related]

  • 4. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, Ottewell PD.
    Clin Exp Metastasis; 2016 Mar 01; 33(3):211-24. PubMed ID: 26585891
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.
    J Natl Cancer Inst; 2008 Aug 20; 100(16):1167-78. PubMed ID: 18695136
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T.
    Clin Cancer Res; 2004 Jul 01; 10(13):4559-67. PubMed ID: 15240548
    [Abstract] [Full Text] [Related]

  • 7. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches.
    Soki FN, Li X, Berry J, Koh A, Sinder BP, Qian X, Kozloff KM, Taichman RS, McCauley LK.
    J Cell Biochem; 2013 Jan 01; 114(1):67-78. PubMed ID: 22833499
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
    Bühler H, Hoberg C, Fakhrian K, Adamietz IA.
    In Vivo; 2013 Jan 01; 30(6):761-768. PubMed ID: 27815459
    [Abstract] [Full Text] [Related]

  • 9. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG, Kanakis I, Gialeli Ch, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK.
    Biochim Biophys Acta; 2013 Jun 01; 1830(6):3625-34. PubMed ID: 23395844
    [Abstract] [Full Text] [Related]

  • 10. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
    Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM.
    Blood; 2012 Jan 12; 119(2):540-50. PubMed ID: 21957195
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
    Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M.
    Cancer Biol Ther; 2012 Dec 12; 13(14):1491-500. PubMed ID: 22990205
    [Abstract] [Full Text] [Related]

  • 12. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 12; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A.
    Clin Cancer Res; 2009 May 15; 15(10):3451-61. PubMed ID: 19401351
    [Abstract] [Full Text] [Related]

  • 14. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.
    Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS.
    Cancer Res; 2018 Sep 15; 78(18):5300-5314. PubMed ID: 30065048
    [Abstract] [Full Text] [Related]

  • 15. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
    Greiner S, Kadow-Romacker A, Schmidmaier G, Wildemann B.
    J Biomed Mater Res A; 2009 Oct 15; 91(1):288-95. PubMed ID: 18980195
    [Abstract] [Full Text] [Related]

  • 16. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.
    Oncotarget; 2017 Jan 31; 8(5):8406-8419. PubMed ID: 28039445
    [Abstract] [Full Text] [Related]

  • 17. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD, Holen I.
    Cell Oncol (Dordr); 2013 Dec 31; 36(6):505-14. PubMed ID: 24177992
    [Abstract] [Full Text] [Related]

  • 18. Osteoclast activity modulates B-cell development in the bone marrow.
    Mansour A, Anginot A, Mancini SJ, Schiff C, Carle GF, Wakkach A, Blin-Wakkach C.
    Cell Res; 2011 Jul 31; 21(7):1102-15. PubMed ID: 21321604
    [Abstract] [Full Text] [Related]

  • 19. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
    Banys M, Solomayer EF, Gebauer G, Janni W, Krawczyk N, Lueck HJ, Becker S, Huober J, Kraemer B, Wackwitz B, Hirnle P, Wallwiener D, Fehm T.
    BMC Cancer; 2013 Oct 15; 13():480. PubMed ID: 24128322
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
    Hung TT, Chan J, Russell PJ, Power CA.
    PLoS One; 2011 Oct 15; 6(5):e19389. PubMed ID: 21603655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.